Development of a Novel KCNN4-Related ceRNA Network and Prognostic Model for Renal Clear Cell Carcinoma

Figure 8

Evaluation of prognostic models and the clinical pharmacological significance of KCNN4. (a) Concordance index curve is used to evaluate the prognostic model. (b) DCA are used to evaluate prognostic models. (c)–(e) The relationship between the expression level of KCNN4 in pan-cancer and the drug sensitivity of cisplatin, sorafenib, and sunitinib. (f)–(h) The relationship between the expression level of KCNN4 in renal carcinoma and the drug sensitivity of cisplatin, sorafenib, and sunitinib.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)